#152743

Anti-PAT4 [PAT-4/9/H10]

Cat. #152743

Anti-PAT4 [PAT-4/9/H10]

Cat. #: 152743

Sub-type: Primary antibody

Unit size: 100 ug

Availability: 3-4 weeks

Target: PAT4 (SLC36A4)

Class: Monoclonal

Application: IHC ; WB

Reactivity: Human

Host: Mouse

£300.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Helen Turley ; Deborah Goberdhan

Institute: University of Oxford

Tool Details
Target Details
Applications
Handling
References

Tool Details

*FOR RESEARCH USE ONLY

  • Name: Anti-PAT4 [PAT-4/9/H10]
  • Clone: PAT-4/9/H10
  • Tool sub type: Primary antibody
  • Class: Monoclonal
  • Conjugation: Unconjugated
  • Molecular weight: ~60 kDa
  • Reactivity: Human
  • Host: Mouse
  • Application: IHC ; WB
  • Description: The Anti-PAT4 [PAT-4/9/H10] antibody is a highly specific mouse monoclonal antibody against PAT4. Members of the proton-assisted amino-acid transporter (PAT) or solute-linked carrier 36 (SLC36) family have been identified as positive regulators of growth and mTORC1 signalling in flies.These effects were shown to be conserved by characterisation of the two ubiquitously transcribed human PATs, PAT1 (SLC36A1) and PAT4 (SLC36A4). PAT4 is upregulated in aggressive forms of colorectal cancer and a possible biomarker.
  • Immunogen: Antigenic amino acid sequence within the N-terminus of PAT4 (REELDMDVMRPLINE-C).
  • Isotype: IgG2a kappa
  • Myeloma used: P3/NS1/1-Ag4.1
  • Recommended controls: 786-O human renal cancer cells

Target Details

  • Target: PAT4 (SLC36A4)
  • Molecular weight: ~60 kDa
  • Tissue cell line specificity: 786-O human renal cancer cells
  • Target background: The Anti-PAT4 [PAT-4/9/H10] antibody is a highly specific mouse monoclonal antibody against PAT4. Members of the proton-assisted amino-acid transporter (PAT) or solute-linked carrier 36 (SLC36) family have been identified as positive regulators of growth and mTORC1 signalling in flies.These effects were shown to be conserved by characterisation of the two ubiquitously transcribed human PATs, PAT1 (SLC36A1) and PAT4 (SLC36A4). PAT4 is upregulated in aggressive forms of colorectal cancer and a possible biomarker.

Applications

  • Application: IHC ; WB

Handling

  • Format: Liquid
  • Concentration: 1.1 mg/ml
  • Unit size: 100 ug
  • Storage buffer: PBS with 0.02% azide
  • Storage conditions: -15° C to -25° C
  • Shipping conditions: Shipping at 4° C

References

  • Fan et al. 2015. Oncogene. :. PMID: 26434594.
  • PAT4 levels control amino-acid sensitivity of rapamycin-resistant mTORC1 from the Golgi and affect clinical outcome in colorectal cancer.